SAGE a leading independent academic and professional publisher today launched Multiple Sclerosis Journal – Experimental, Translational and Clinical as an open access (OA) peer reviewed journal.
The OA companion to Multiple Sclerosis Journal, this new publication publishes across the broad spectrum of MS related issues including experimental, translational and clinical topics. Areas of focus include; early validation of clinical outcome metrics, pilot trials which may stimulate therapeutic invocation, specialised areas of experimental, translational and clinical research with an international focus and emerging observations with a translational potential.
Speaking of the launch, Karen Phillips, Editorial Director, SAGE commented:
“The addition of Multiple Sclerosis Journal – Experimental, Translational and Clinical to our OA portfolio, is a very exciting addition for us and one that further strengthens access to this vital research within this influential field. We are building a strong portfolio of journals within the health sciences and neurology disciplines and we are very excited to be launching this OA journal to further expand international reach and coverage. Working with a highly regarded editorial board, we look forward to developing a longstanding and influential relationship as the scope and research of the journal continues to expand.”
Alan Thompson, Editor in Chief of Multiple Sclerosis Journal said of the launch:
“The field of research into multiple sclerosis is continuing to evolve and we are incredibly excited to be able to expand the discipline and international research coverage through the launch of this new open access journal. We will be able to include high quality articles on emerging observations with translational potential, early validation of clinical outcome metrics, pilot trials which may stimulate therapeutic innovation and highly specialized areas of experimental, translational and clinical research. We have a dynamic, international team of editors which will work closely with the editorial team of MSJ which will make this an exciting new initiative and one that we look forward to developing.”
The website for the journal is: – http://sagepub.com/msjetc
September 9, 2014
Author: James Douglas
SAGE launches new OA journal, Multiple Sclerosis Journal – Experimental, Translational and Clinical
SAGE a leading independent academic and professional publisher today launched Multiple Sclerosis Journal – Experimental, Translational and Clinical as an open access (OA) peer reviewed journal.
The OA companion to Multiple Sclerosis Journal, this new publication publishes across the broad spectrum of MS related issues including experimental, translational and clinical topics. Areas of focus include; early validation of clinical outcome metrics, pilot trials which may stimulate therapeutic invocation, specialised areas of experimental, translational and clinical research with an international focus and emerging observations with a translational potential.
Speaking of the launch, Karen Phillips, Editorial Director, SAGE commented:
“The addition of Multiple Sclerosis Journal – Experimental, Translational and Clinical to our OA portfolio, is a very exciting addition for us and one that further strengthens access to this vital research within this influential field. We are building a strong portfolio of journals within the health sciences and neurology disciplines and we are very excited to be launching this OA journal to further expand international reach and coverage. Working with a highly regarded editorial board, we look forward to developing a longstanding and influential relationship as the scope and research of the journal continues to expand.”
Alan Thompson, Editor in Chief of Multiple Sclerosis Journal said of the launch:
“The field of research into multiple sclerosis is continuing to evolve and we are incredibly excited to be able to expand the discipline and international research coverage through the launch of this new open access journal. We will be able to include high quality articles on emerging observations with translational potential, early validation of clinical outcome metrics, pilot trials which may stimulate therapeutic innovation and highly specialized areas of experimental, translational and clinical research. We have a dynamic, international team of editors which will work closely with the editorial team of MSJ which will make this an exciting new initiative and one that we look forward to developing.”
The website for the journal is: – http://sagepub.com/msjetc
September 9, 2014
Author: James Douglas